NASDAQ : EVGN
Evogene Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 0.3804 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.06M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.84M |
| Enterprise Value | 7.59M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 19, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 15.80M |
| Shares Outstanding | 13.54M |
| Shares Change (YoY) | +51.18% |
| Shares Change (QoQ) | +25.28% |
| Owned by Insiders (%) | 8.51% |
| Owned by Institutions (%) | 5.51% |
| Float | 14.46M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.53 |
| Forward PS | 7.74 |
| PB Ratio | 1.01 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.57 |
| Quick Ratio | 3.23 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -182.75% |
| Return on Assets (ROA) | -37.53% |
| Return on Invested Capital (ROIC) | -77.61% |
| Return on Capital Employed (ROCE) | -136.78% |
| Weighted Average Cost of Capital (WACC) | 6.02% |
| Revenue Per Employee | $31,865 |
| Profits Per Employee | -$174,481 |
| Employee Count | 52 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 2.71 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.72 |
| 52-Week Price Change | -70.73% |
| 50-Day Moving Average | 0.45 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 41.81 |
| Average Volume (20 Days) | 105,164 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 63,883 |
| Short Previous Month | 932,725 |
| Short % of Shares Out | 0.36% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.66M |
| Gross Profit | -1.12M |
| Operating Income | -14.22M |
| Pretax Income | -16.58M |
| Net Income | -9.07M |
| EBITDA | -13.87M |
| EBIT | -14.22M |
| Loss Per Share | -$0.85 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 9.32M |
| Total Debt | 2.10M |
| Net Cash | 7.22M |
| Net Cash Per Share | $0.53 |
| Equity (Book Value) | 5.77M |
| Book Value Per Share | -0.24 |
| Working Capital | 7.81M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.95M |
| Capital Expenditures | -24,000 |
| Depreciation & Amortization | 351,000 |
| Net Borrowing | -511,000 |
| Free Cash Flow | -10.97M |
| FCF Per Share | -$0.81 |
Margins
| Measure | Value |
|---|
| Gross Margin | -67.59% |
| Operating Margin | -858.18% |
| Pretax Margin | -1,000.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -51.18% |
| Shareholder Yield | -51.18% |
| Earnings Yield | -228.20% |
| FCF Yield | -187.81% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 8.71% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -32.17 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |